이상지혈증을 동반한 제2형 당뇨병환자에서 미세화된 fenofibrate 제제와 서방형 fenoflbrate제제의 효능비교 연구

Comparison of Efficacy Between Micronised- and Non-micronised Fenofibrate in Type 2 Diabetic Patients with Dyslipidemia

Fenofibrate is a fibric acid derivative that is a strong reducer of triglyceride. Micronized formulation of fenofibrate has improved bioavailability compared to non- micrornized formulation. This study performed a retrospective comparison of micronized and non-micronized fenofibrate (28 in micronized and 51 in non-micronized group) by comparing the means of changes in total triglyceride, total cholesterol, HDL- cholesterol and TC/HDL ratio in type 2 diabetics with dyslipidemia. The result showed that after 12 weeks of treatment both drugs produced a significant reduction in total triglyceride levels (62% with micronized, 37% with non-micronized). The mean decrease observed for total triglyceride levels were signnificantly lower for micronized fenofibrate (p<0.001). Both drugs showed a significant reduction for total cholesterol levels (-22% with micronized, -14% with non-micronized fenofibrate). The mean decrease observed for total cholesterol was not significantly different between the two drugs (p>0.05). HDL-cholesterol levels increased by 24% and 15% with micronized and non- micronized, respectively and the differences from the baseline were statistically significant for both drugs (p<0.05). The mean change of HDL-cholesterol was not significantly different between the two drugs. There was a statistically significant reduction in TC/HDL-cholesterol ratio from baseline for both drugs (7.1 to 4.8 with micronized and 5.1 to 4.5 with non-micronized), and the reduction of TC/HDl.- cholesterol ratio tended to be significantly greater with micronized fenofibrate (p<0.05). This study shows that short-term treatment with microni3ed fenofibrate is more effective than non-micronized fenofibrate in type 2 diabetes patients with dyslipidemia.